Boehringer reports Phase III data for nintedanib in interstitial lung disease

Boehringer Ingelheim has reported findings from the Phase III InPedILD clinical trial of nintedanib to treat fibrosing interstitial lung disease (ILD) in children and adolescents aged six to 17 years.